111 Capital’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RXRX
AIM
MCMU
111 Capital's RXRX Position: Q2 2026 in Review
111 Capital opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 26,198 shares worth $96.1K. The stake represents 0.02% of the portfolio and ranks #480 among its holdings. This is a return to the name: 111 Capital previously reported a position in RXRX as recently as Q1 2025.
111 Capital first reported a position in RXRX in Q1 2025 and has held it in 2 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.
- 111 Capital held 26,198 shares of Recursion Pharmaceuticals worth $96.1K as of Q2 2026.
- Recursion Pharmaceuticals was a new 111 Capital position in Q2 2026.
- Recursion Pharmaceuticals made up 0.02% of 111 Capital's portfolio in Q2 2026, its #480 holding.
- 111 Capital first reported a position in Recursion Pharmaceuticals in Q1 2025 and has held it in 2 quarters since.
- 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.
Based on 111 Capital's 13F filing for Q2 2026, filed 5 Aug 2026.